
Krystal Biotech, Inc. (NASDAQ: KRYS) Stock Competitors & Peer Comparison
See KRYS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for KRYS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KRYS | $305.23 | -0.15% | 9B | 38.25 | $7.98 | N/A |
| VRTX | $538.60 | -0.74% | 136.6B | 28.30 | $19.03 | N/A |
| REGN | $955.47 | +0.45% | 98.8B | 20.94 | $45.63 | +0.38% |
| MRNA | $223.37 | -3.45% | 90.4B | -27.41 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $960.04 | -2.17% | 60B | 34.62 | $27.73 | N/A |
| ONC | $416.54 | +0.14% | 44.5B | 73.33 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $172.29 | -2.30% | 37.3B | -19.53 | -$8.82 | N/A |
| RVMDW | $7.68 | -5.83% | 35.9B | -0.87 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
KRYS vs VRTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, VRTX has a market cap of 136.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while VRTX trades at $538.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas VRTX's P/E ratio is 28.30. In terms of profitability, KRYS's ROE is +0.17%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, KRYS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
KRYS vs REGN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, REGN has a market cap of 98.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while REGN trades at $955.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas REGN's P/E ratio is 20.94. In terms of profitability, KRYS's ROE is +0.17%, compared to REGN's ROE of +0.15%. Regarding short-term risk, KRYS is similarly volatile compared to REGN. This indicates similar risk in terms of short-term price fluctuations for KRYS.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
KRYS vs MRNA Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MRNA has a market cap of 90.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MRNA trades at $223.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MRNA's P/E ratio is -27.41. In terms of profitability, KRYS's ROE is +0.17%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, KRYS is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
KRYS vs VRNA Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas VRNA's P/E ratio is -102.80. In terms of profitability, KRYS's ROE is +0.17%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, KRYS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
KRYS vs ARGX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ARGX has a market cap of 60B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ARGX trades at $960.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ARGX's P/E ratio is 34.62. In terms of profitability, KRYS's ROE is +0.17%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, KRYS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
KRYS vs ONC Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ONC has a market cap of 44.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ONC trades at $416.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ONC's P/E ratio is 73.33. In terms of profitability, KRYS's ROE is +0.17%, compared to ONC's ROE of +0.18%. Regarding short-term risk, KRYS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
KRYS vs SGEN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas SGEN's P/E ratio is -57.19. In terms of profitability, KRYS's ROE is +0.17%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, KRYS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
KRYS vs RVMD Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RVMD has a market cap of 37.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RVMD trades at $172.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RVMD's P/E ratio is -19.53. In terms of profitability, KRYS's ROE is +0.17%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, KRYS is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
KRYS vs RVMDW Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RVMDW has a market cap of 35.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RVMDW trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RVMDW's P/E ratio is -0.87. In terms of profitability, KRYS's ROE is +0.17%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, KRYS is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
KRYS vs GMAB Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, GMAB has a market cap of 31.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while GMAB trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas GMAB's P/E ratio is 38.71. In terms of profitability, KRYS's ROE is +0.17%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, KRYS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
KRYS vs ROIV Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ROIV has a market cap of 28.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ROIV trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ROIV's P/E ratio is -37.61. In terms of profitability, KRYS's ROE is +0.17%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, KRYS is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
KRYS vs INSM Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, INSM has a market cap of 26.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while INSM trades at $121.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas INSM's P/E ratio is -42.96. In terms of profitability, KRYS's ROE is +0.17%, compared to INSM's ROE of -0.83%. Regarding short-term risk, KRYS is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
KRYS vs UTHR Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while UTHR trades at $591.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas UTHR's P/E ratio is 21.15. In terms of profitability, KRYS's ROE is +0.17%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, KRYS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
KRYS vs INCY Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while INCY trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas INCY's P/E ratio is 16.26. In terms of profitability, KRYS's ROE is +0.17%, compared to INCY's ROE of +0.07%. Regarding short-term risk, KRYS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
KRYS vs ALNY Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ALNY has a market cap of 22.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ALNY trades at $165.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ALNY's P/E ratio is 8.34. In terms of profitability, KRYS's ROE is +0.17%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, KRYS is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
KRYS vs BNTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, BNTX has a market cap of 21.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while BNTX trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas BNTX's P/E ratio is -11.10. In terms of profitability, KRYS's ROE is +0.17%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, KRYS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
KRYS vs BGNE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas BGNE's P/E ratio is -22.55. In terms of profitability, KRYS's ROE is +0.17%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, KRYS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
KRYS vs DNA-WT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, KRYS's ROE is +0.17%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, KRYS is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
KRYS vs ASND Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ASND has a market cap of 18.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ASND trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ASND's P/E ratio is -113.80. In terms of profitability, KRYS's ROE is +0.17%, compared to ASND's ROE of +1.08%. Regarding short-term risk, KRYS is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
KRYS vs EXEL Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, EXEL has a market cap of 17.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while EXEL trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas EXEL's P/E ratio is 19.71. In terms of profitability, KRYS's ROE is +0.17%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, KRYS is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
KRYS vs NBIX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while NBIX trades at $167.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas NBIX's P/E ratio is 24.19. In terms of profitability, KRYS's ROE is +0.17%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, KRYS is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
KRYS vs JAZZ Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while JAZZ trades at $241.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas JAZZ's P/E ratio is 9.01. In terms of profitability, KRYS's ROE is +0.17%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, KRYS is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
KRYS vs BBIO Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while BBIO trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas BBIO's P/E ratio is -25.76. In terms of profitability, KRYS's ROE is +0.17%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, KRYS is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
KRYS vs KRTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas KRTX's P/E ratio is -28.09. In terms of profitability, KRYS's ROE is +0.17%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, KRYS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
KRYS vs TECH Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TECH's P/E ratio is 37.53. In terms of profitability, KRYS's ROE is +0.17%, compared to TECH's ROE of +0.08%. Regarding short-term risk, KRYS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check TECH's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
KRYS vs HALO Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, HALO has a market cap of 11.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while HALO trades at $100.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas HALO's P/E ratio is 18.71. In terms of profitability, KRYS's ROE is +0.17%, compared to HALO's ROE of +5.44%. Regarding short-term risk, KRYS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check HALO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
KRYS vs SMMT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while SMMT trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas SMMT's P/E ratio is -12.63. In terms of profitability, KRYS's ROE is +0.17%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, KRYS is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check SMMT's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
KRYS vs RNAM Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RNAM's P/E ratio is -17.39. In terms of profitability, KRYS's ROE is +0.17%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, KRYS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
KRYS vs BMRN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while BMRN trades at $57.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas BMRN's P/E ratio is 27.51. In terms of profitability, KRYS's ROE is +0.17%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, KRYS is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BMRN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
KRYS vs KYMR Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, KYMR has a market cap of 10.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while KYMR trades at $127.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas KYMR's P/E ratio is -35.24. In terms of profitability, KRYS's ROE is +0.17%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, KRYS is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check KYMR's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
KRYS vs PCVX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while PCVX trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas PCVX's P/E ratio is -8.31. In terms of profitability, KRYS's ROE is +0.17%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, KRYS is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PCVX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
KRYS vs MDGL Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MDGL trades at $427.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MDGL's P/E ratio is -33.39. In terms of profitability, KRYS's ROE is +0.17%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, KRYS is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MDGL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
KRYS vs SYRE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, SYRE has a market cap of 9.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while SYRE trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas SYRE's P/E ratio is -53.33. In terms of profitability, KRYS's ROE is +0.17%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, KRYS is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
KRYS vs TGTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TGTX has a market cap of 9.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TGTX trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TGTX's P/E ratio is 23.37. In terms of profitability, KRYS's ROE is +0.17%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, KRYS is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TGTX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
KRYS vs RXDX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RXDX's P/E ratio is -56.47. In terms of profitability, KRYS's ROE is +0.17%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, KRYS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
KRYS vs PRAX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while PRAX trades at $328.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas PRAX's P/E ratio is -25.38. In terms of profitability, KRYS's ROE is +0.17%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, KRYS is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
KRYS vs NUVL Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas NUVL's P/E ratio is -21.79. In terms of profitability, KRYS's ROE is +0.17%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, KRYS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
KRYS vs CRNX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CRNX's P/E ratio is -16.86. In terms of profitability, KRYS's ROE is +0.17%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, KRYS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
KRYS vs IMGN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas IMGN's P/E ratio is -111.55. In terms of profitability, KRYS's ROE is +0.17%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, KRYS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
KRYS vs PTGX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while PTGX trades at $130.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas PTGX's P/E ratio is 127.14. In terms of profitability, KRYS's ROE is +0.17%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, KRYS is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
KRYS vs APGE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas APGE's P/E ratio is -31.19. In terms of profitability, KRYS's ROE is +0.17%, compared to APGE's ROE of -0.30%. Regarding short-term risk, KRYS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
KRYS vs BPMC Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas BPMC's P/E ratio is -51.58. In terms of profitability, KRYS's ROE is +0.17%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, KRYS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
KRYS vs CERE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CERE's P/E ratio is -16.47. In terms of profitability, KRYS's ROE is +0.17%, compared to CERE's ROE of -0.72%. Regarding short-term risk, KRYS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
KRYS vs RYTM Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RYTM has a market cap of 8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RYTM trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RYTM's P/E ratio is -36.98. In terms of profitability, KRYS's ROE is +0.17%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, KRYS is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RYTM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
KRYS vs CYTK Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CYTK trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CYTK's P/E ratio is -7.77. In terms of profitability, KRYS's ROE is +0.17%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, KRYS is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
KRYS vs ABVX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ABVX trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ABVX's P/E ratio is -14.35. In terms of profitability, KRYS's ROE is +0.17%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, KRYS is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
KRYS vs AXSM Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, AXSM has a market cap of 7.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while AXSM trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas AXSM's P/E ratio is -36.99. In terms of profitability, KRYS's ROE is +0.17%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, KRYS is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check AXSM's competition here
Metsera, Inc. (NASDAQ: MTSR)
KRYS vs MTSR Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MTSR's P/E ratio is -23.58. In terms of profitability, KRYS's ROE is +0.17%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, KRYS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check MTSR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
KRYS vs TWST Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TWST has a market cap of 7.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TWST trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TWST's P/E ratio is -50.27. In terms of profitability, KRYS's ROE is +0.17%, compared to TWST's ROE of -0.23%. Regarding short-term risk, KRYS is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TWST's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
KRYS vs ORKA Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ORKA trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ORKA's P/E ratio is -54.30. In terms of profitability, KRYS's ROE is +0.17%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, KRYS is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ORKA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
KRYS vs IMVT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, IMVT has a market cap of 7.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while IMVT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas IMVT's P/E ratio is -12.12. In terms of profitability, KRYS's ROE is +0.17%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, KRYS is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
KRYS vs TXG Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TXG has a market cap of 7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TXG trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TXG's P/E ratio is -98.63. In terms of profitability, KRYS's ROE is +0.17%, compared to TXG's ROE of -0.08%. Regarding short-term risk, KRYS is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TXG's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
KRYS vs KOD Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, KOD has a market cap of 7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while KOD trades at $111.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas KOD's P/E ratio is -26.66. In terms of profitability, KRYS's ROE is +0.17%, compared to KOD's ROE of -2.88%. Regarding short-term risk, KRYS is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
KRYS vs MRUS Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MRUS's P/E ratio is -17.05. In terms of profitability, KRYS's ROE is +0.17%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, KRYS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check MRUS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
KRYS vs ARWR Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ARWR has a market cap of 6.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ARWR trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ARWR's P/E ratio is -21.24. In terms of profitability, KRYS's ROE is +0.17%, compared to ARWR's ROE of -0.75%. Regarding short-term risk, KRYS is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ARWR's competition here
Arcellx, Inc. (NASDAQ: ACLX)
KRYS vs ACLX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ACLX's P/E ratio is -28.27. In terms of profitability, KRYS's ROE is +0.17%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, KRYS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
KRYS vs CGON Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CGON trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CGON's P/E ratio is -27.66. In terms of profitability, KRYS's ROE is +0.17%, compared to CGON's ROE of -0.25%. Regarding short-term risk, KRYS is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
KRYS vs BLTE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while BLTE trades at $164.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas BLTE's P/E ratio is -87.89. In terms of profitability, KRYS's ROE is +0.17%, compared to BLTE's ROE of -0.17%. Regarding short-term risk, KRYS is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
KRYS vs CAI Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CAI has a market cap of 6.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CAI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CAI's P/E ratio is 64.74. In terms of profitability, KRYS's ROE is +0.17%, compared to CAI's ROE of +0.16%. Regarding short-term risk, KRYS is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CAI's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
KRYS vs RETA Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RETA's P/E ratio is -66.29. In terms of profitability, KRYS's ROE is +0.17%, compared to RETA's ROE of +0.47%. Regarding short-term risk, KRYS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RETA's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
KRYS vs IBRX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, IBRX has a market cap of 6.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while IBRX trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas IBRX's P/E ratio is -6.21. In terms of profitability, KRYS's ROE is +0.17%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, KRYS is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IBRX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
KRYS vs CNTA Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CNTA's P/E ratio is -22.63. In terms of profitability, KRYS's ROE is +0.17%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, KRYS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
KRYS vs LGND Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while LGND trades at $308.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas LGND's P/E ratio is 33.90. In terms of profitability, KRYS's ROE is +0.17%, compared to LGND's ROE of +0.05%. Regarding short-term risk, KRYS is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check LGND's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
KRYS vs MIRM Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MIRM trades at $93.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MIRM's P/E ratio is -6.46. In terms of profitability, KRYS's ROE is +0.17%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, KRYS is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
KRYS vs TERN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TERN's P/E ratio is -51.41. In terms of profitability, KRYS's ROE is +0.17%, compared to TERN's ROE of -0.14%. Regarding short-term risk, KRYS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check TERN's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
KRYS vs CDTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CDTX's P/E ratio is -19.77. In terms of profitability, KRYS's ROE is +0.17%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, KRYS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
KRYS vs ABCM Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, KRYS's ROE is +0.17%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, KRYS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
KRYS vs ISEE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ISEE's P/E ratio is -22.44. In terms of profitability, KRYS's ROE is +0.17%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, KRYS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
KRYS vs ERAS Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ERAS trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ERAS's P/E ratio is -16.84. In terms of profitability, KRYS's ROE is +0.17%, compared to ERAS's ROE of -0.62%. Regarding short-term risk, KRYS is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
KRYS vs MANE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MANE has a market cap of 5.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MANE trades at $129.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MANE's P/E ratio is -41.27. In terms of profitability, KRYS's ROE is +0.17%, compared to MANE's ROE of -0.20%. Regarding short-term risk, KRYS is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check MANE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
KRYS vs PTCT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while PTCT trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas PTCT's P/E ratio is -45.35. In terms of profitability, KRYS's ROE is +0.17%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, KRYS is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
KRYS vs SRRK Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while SRRK trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas SRRK's P/E ratio is -12.52. In terms of profitability, KRYS's ROE is +0.17%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, KRYS is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
KRYS vs APLS Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas APLS's P/E ratio is 38.35. In terms of profitability, KRYS's ROE is +0.17%, compared to APLS's ROE of +0.40%. Regarding short-term risk, KRYS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check APLS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
KRYS vs DNTH Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, DNTH has a market cap of 5.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while DNTH trades at $91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas DNTH's P/E ratio is -22.12. In terms of profitability, KRYS's ROE is +0.17%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, KRYS is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
KRYS vs COGT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, COGT has a market cap of 5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while COGT trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas COGT's P/E ratio is -13.54. In terms of profitability, KRYS's ROE is +0.17%, compared to COGT's ROE of -0.71%. Regarding short-term risk, KRYS is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check COGT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
KRYS vs EWTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas EWTX's P/E ratio is -24.83. In terms of profitability, KRYS's ROE is +0.17%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, KRYS is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check EWTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
KRYS vs TVTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TVTX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TVTX's P/E ratio is -112.56. In terms of profitability, KRYS's ROE is +0.17%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, KRYS is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TVTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
KRYS vs IONS Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, IONS has a market cap of 4.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while IONS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas IONS's P/E ratio is -8.89. In terms of profitability, KRYS's ROE is +0.17%, compared to IONS's ROE of -1.20%. Regarding short-term risk, KRYS is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IONS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
KRYS vs ADPT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ADPT trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ADPT's P/E ratio is -70.83. In terms of profitability, KRYS's ROE is +0.17%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, KRYS is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
KRYS vs FOLD Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas FOLD's P/E ratio is -161.00. In terms of profitability, KRYS's ROE is +0.17%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, KRYS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
KRYS vs AKRO Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas AKRO's P/E ratio is -14.57. In terms of profitability, KRYS's ROE is +0.17%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, KRYS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
KRYS vs ALPN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ALPN's P/E ratio is -101.52. In terms of profitability, KRYS's ROE is +0.17%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, KRYS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
KRYS vs DFTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while DFTX trades at $32.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas DFTX's P/E ratio is N/A. In terms of profitability, KRYS's ROE is +0.17%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, KRYS is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check DFTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
KRYS vs TNGX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TNGX trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TNGX's P/E ratio is -30.72. In terms of profitability, KRYS's ROE is +0.17%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, KRYS is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
KRYS vs OPT Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas OPT's P/E ratio is -1.52. In terms of profitability, KRYS's ROE is +0.17%, compared to OPT's ROE of +1.18%. Regarding short-term risk, KRYS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
KRYS vs PRTC Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas PRTC's P/E ratio is -3.78. In terms of profitability, KRYS's ROE is +0.17%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, KRYS is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
KRYS vs MRTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas MRTX's P/E ratio is -4.82. In terms of profitability, KRYS's ROE is +0.17%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, KRYS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check MRTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
KRYS vs CRSP Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CRSP trades at $42.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CRSP's P/E ratio is -8.87. In terms of profitability, KRYS's ROE is +0.17%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, KRYS is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
KRYS vs RLAY Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RLAY trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RLAY's P/E ratio is -11.52. In terms of profitability, KRYS's ROE is +0.17%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, KRYS is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check RLAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
KRYS vs XENE Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while XENE trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas XENE's P/E ratio is -8.61. In terms of profitability, KRYS's ROE is +0.17%, compared to XENE's ROE of -0.40%. Regarding short-term risk, KRYS is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check XENE's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
KRYS vs TARS Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, TARS has a market cap of 4B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while TARS trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas TARS's P/E ratio is -73.65. In terms of profitability, KRYS's ROE is +0.17%, compared to TARS's ROE of -2.46%. Regarding short-term risk, KRYS is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check TARS's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
KRYS vs AMLX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while AMLX trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas AMLX's P/E ratio is -20.19. In terms of profitability, KRYS's ROE is +0.17%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, KRYS is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check AMLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
KRYS vs CPRX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CPRX's P/E ratio is 17.49. In terms of profitability, KRYS's ROE is +0.17%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, KRYS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
KRYS vs ABCL Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ABCL trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ABCL's P/E ratio is -21.28. In terms of profitability, KRYS's ROE is +0.17%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, KRYS is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
KRYS vs RYZB Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas RYZB's P/E ratio is -57.86. In terms of profitability, KRYS's ROE is +0.17%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, KRYS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
KRYS vs CBAY Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas CBAY's P/E ratio is -32.81. In terms of profitability, KRYS's ROE is +0.17%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, KRYS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for KRYS.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
KRYS vs VKTX Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while VKTX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas VKTX's P/E ratio is -5.41. In terms of profitability, KRYS's ROE is +0.17%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, KRYS is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check VKTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
KRYS vs ELVN Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while ELVN trades at $48.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas ELVN's P/E ratio is -29.22. In terms of profitability, KRYS's ROE is +0.17%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, KRYS is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check ELVN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
KRYS vs IOVA Comparison November 2026
Krystal Biotech, Inc. (NASDAQ: KRYS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KRYS stands at 9B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, KRYS is priced at $305.23 on the NASDAQ, while IOVA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KRYS currently has a P/E ratio of 38.25, whereas IOVA's P/E ratio is -10.63. In terms of profitability, KRYS's ROE is +0.17%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, KRYS is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for KRYS.Check IOVA's competition here